These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

245 related articles for article (PubMed ID: 37208427)

  • 1. Angiographic biomarkers are significant predictors of treatment response to intravitreal aflibercept in diabetic macular edema.
    Hein M; Vukmirovic A; Constable IJ; Raja V; Athwal A; Freund KB; Balaratnasingam C
    Sci Rep; 2023 May; 13(1):8128. PubMed ID: 37208427
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Optical Coherence Tomography Angiography in Diabetic Macular Edema Treated with Intravitreal Aflibercept: A 48-Week Observational Study (the DOCTA Study).
    Korobelnik JF; Gaucher D; Baillif S; Creuzot-Garcher C; Kodjikian L; Weber M
    Ophthalmologica; 2023; 246(2):71-80. PubMed ID: 36646050
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Optical coherence tomography classifications of diabetic macular edema and response to aflibercept: One-year follow-up outcomes in a Chinese population.
    Gu Z; Xi T; Zhang C; Yang G
    Medicine (Baltimore); 2023 Jan; 102(4):e32815. PubMed ID: 36705371
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Treatment response to Conbercept of different types of diabetic macular edema classified based on optical coherence tomography].
    Zhang Y; Yao J; Quan Y; Wang J; Xing Y; Zhou A
    Nan Fang Yi Ke Da Xue Xue Bao; 2021 Oct; 41(10):1501-1508. PubMed ID: 34755665
    [TBL] [Abstract][Full Text] [Related]  

  • 5. OCTA changes following loading phase with intravitreal aflibercept for DME.
    Kansal V; Colleaux K; Rawlings N
    Can J Ophthalmol; 2023 Oct; 58(5):480-490. PubMed ID: 35526615
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Functional and morphological changes in diabetic macular edema over the course of anti-vascular endothelial growth factor treatment.
    Reznicek L; Cserhati S; Seidensticker F; Liegl R; Kampik A; Ulbig M; Neubauer AS; Kernt M
    Acta Ophthalmol; 2013 Nov; 91(7):e529-36. PubMed ID: 23647578
    [TBL] [Abstract][Full Text] [Related]  

  • 7. EFFECT OF BASELINE CENTRAL RETINAL THICKNESS ON THE RESULTS OF TREATMENT OF DIABETIC MACULAR EDEMA WITH AFLIBERCEPT: REAL-LIFE EVIDENCE IN THE CZECH REPUBLIC.
    Němčanský J; Stepanov A; Veith M; Koubek M; Kopecký A; Němčanská S; Beran D; Studnička J
    Cesk Slov Oftalmol; 2022; 78(2):64-70. PubMed ID: 35477246
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The Impact of Laboratory Findings and Optical Coherence Tomography Biomarkers on Response to Intravitreal Anti-VEGF Treatment in Patients with Diabetic Macular Edema.
    Chatziralli I; Dimitriou E; Lambadiari V; Kazantzis D; Kapsis P; Theodossiadis G; Theodossiadis P; Sergentanis TN
    Semin Ophthalmol; 2022 Jul; 37(5):668-675. PubMed ID: 35468026
    [TBL] [Abstract][Full Text] [Related]  

  • 9. MEASUREMENTS OF RETINAL FLUID BY OPTICAL COHERENCE TOMOGRAPHY LEAKAGE IN DIABETIC MACULAR EDEMA: A Biomarker of Visual Acuity Response to Treatment.
    Santos AR; Alves D; Santos T; Figueira J; Silva R; Cunha-Vaz JG
    Retina; 2019 Jan; 39(1):52-60. PubMed ID: 29077605
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Optical Coherence Tomography Biomarkers in Predicting Treatment Outcomes of Diabetic Macular Edema after Ranibizumab Injections.
    Chang YC; Huang YT; Hsu AY; Meng PP; Lin CJ; Lai CT; Hsia NY; Chen HS; Tien PT; Lin JM; Chen WL; Tsai YY
    Medicina (Kaunas); 2023 Mar; 59(3):. PubMed ID: 36984630
    [No Abstract]   [Full Text] [Related]  

  • 11. Switching therapy from bevacizumab to aflibercept for the management of persistent diabetic macular edema.
    Bahrami B; Hong T; Zhu M; Schlub TE; Chang A
    Graefes Arch Clin Exp Ophthalmol; 2017 Jun; 255(6):1133-1140. PubMed ID: 28238195
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Temporal variation of optical coherence tomography biomarkers as predictors of anti-VEGF treatment outcomes in diabetic macular edema.
    Maggio E; Mete M; Sartore M; Bauci F; Guerriero M; Polito A; Pertile G
    Graefes Arch Clin Exp Ophthalmol; 2022 Mar; 260(3):807-815. PubMed ID: 34661731
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Ranibizumab versus aflibercept for diabetic macular edema: 18-month results of a comparative, prospective, randomized study and multivariate analysis of visual outcome predictors.
    Chatzirallis A; Theodossiadis P; Droutsas K; Koutsandrea C; Ladas I; Moschos MM
    Cutan Ocul Toxicol; 2020 Dec; 39(4):317-322. PubMed ID: 32722955
    [TBL] [Abstract][Full Text] [Related]  

  • 14. COMPARISON OF INTRAVITREAL DEXAMETHASONE IMPLANT AND AFLIBERCEPT IN PATIENTS WITH TREATMENT-NAIVE DIABETIC MACULAR EDEMA WITH SEROUS RETINAL DETACHMENT.
    Ozsaygili C; Duru N
    Retina; 2020 Jun; 40(6):1044-1052. PubMed ID: 30950970
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Suprachoroidal CLS-TA plus Intravitreal Aflibercept for Diabetic Macular Edema: A Randomized, Double-Masked, Parallel-Design, Controlled Study.
    Barakat MR; Wykoff CC; Gonzalez V; Hu A; Marcus D; Zavaleta E; Ciulla TA
    Ophthalmol Retina; 2021 Jan; 5(1):60-70. PubMed ID: 32829027
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dril Influences Short-term Visual Outcome after Intravitreal Corticosteroid Injection for Refractory Diabetic Macular Edema.
    Luís ME; Sampaio F; Costa J; Cabral D; Teixeira C; Ferreira JT
    Curr Eye Res; 2021 Sep; 46(9):1378-1386. PubMed ID: 33463388
    [No Abstract]   [Full Text] [Related]  

  • 17. Optical Coherence Tomography-Based Grading of Diabetic Macular Edema Is Associated with Systemic Inflammatory Indices and Imaging Biomarkers.
    Yanxia C; Xiongyi Y; Min F; Xiaoyun K
    Ophthalmic Res; 2024; 67(1):96-106. PubMed ID: 38211574
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Optical coherence tomography angiography analysis of macular vessel density before and after anti-VEGF therapy in eyes with diabetic retinopathy.
    Sorour OA; Sabrosa AS; Yasin Alibhai A; Arya M; Ishibazawa A; Witkin AJ; Baumal CR; Duker JS; Waheed NK
    Int Ophthalmol; 2019 Oct; 39(10):2361-2371. PubMed ID: 31119505
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Functional and anatomic results of up to 24 months aflibercept treatment for diabetic macular edema in real-life setting.
    Tsapardoni FN; Makri OE; Lagogiannis AP; Tsekouras IK; Chairas N; Pallikari A; Pagoulatos DD; Georgakopoulos CD
    Hell J Nucl Med; 2019; 22 Suppl 2():47-54. PubMed ID: 31802045
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Ranibizumab and aflibercept for diabetic macular edema-retrospective study with real-life data after 12 months].
    Holbach B; Zeman F; Helbig H; Gamulescu MA
    Ophthalmologe; 2020 Jul; 117(7):687-692. PubMed ID: 31705192
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.